Hong Kong firm looks to fill gap in market for kidney disease treatments

18 October 2019

Hong Kong-based artificial intelligence specialist Great Bay Bio has launched a strategic cooperation with Boji Medical to jointly develop GBB101, a new long-acting injectable biologic.

Boji Medical, a contract development and manufacturing organization (CDMO), will work with Great Bay to develop the biologic as an option for anemia caused by chronic kidney disease (CKD).

The prevalence of CKD in China has been increasing significantly in recent years, with the overall number of CKD patients estimated to be around 130 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK